Presentation of the 4th financing round of
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Presentation of the 4th
financing round of
CEBIOTEX
October - December 2020
Objetives:
• Finish Clinical phase 2a, activity,
in adult Sarcomas (STS).
• Initiate Clinical Phases in pediatric
cancer, in collaboration with SJD
Pediatric Cancer Center
Barcelona.
• FDA: ODD (Orphan Drug
Designation) – preIND meeting
Company introduction
• CEBIOTEX S.L., is a spin-off of the Sant Joan de
Déu Hospital of Barcelona (HSJD) and the
Polytechnic University of Catalonia (UPC). It started
its activity in 2015, based at Pier01 Barcelona.
Innovative SME and Technology-Based Company,
focused on providing new and innovative solutions
to the HEALTH Sector, with a high social and
economic impact..
• The Cebiotex Project arises when Sara, a 6-year-
old girl, leaves us after fighting cancer for 4 years. At
that time, as a result of impotence in the fight against
cancer, J.Bertran, founder of the Company, decided
to investigate new drugs, based on biomembranes, The 1st drug that emerged from the CEBIOTEX®
that provide medical solutions and specifically technological platform is “CEB-01”. Indicated for the
solutions to cancer, including pediatric cancer. local control of the surgical beds after an oncological
surgical intervention in the indication of Soft Tissue
• The CEBIOTEX® platform is the first Bio-Material
Sarcoma (STS). The efficacy results in animals and
developed and patented by Cebiotex together with
toxicology have been extremely promising in the Drug
HSJD and UPC. It aims to provide an innovative and
Discovery, in-vivo and Pre-Clinical Regulatory phases.
effective solution to the "Local Drug Delivery" of
drugs and biologics. The “First in Men” (Clinical Phase I, safety) just started,
and results so far are that no toxicity or side effect
• It is part of the Company's Mission to develop its
appeared in the patients.
products for the health of both adults and children.
This round of funding should allow us to start the Clinical
Phase 2a, activity, of CEB-01 with 21 adult patients in
Soft Tissue Sarcoma
Table of contents
1. Product
2. Business model
3. Market/portfolio
4. Competitors
5. Intelectual property rights
6. Milestones achieved
7. Team
8. Shareholders
9. 4th funding round
10. Exit strategy
Image: surgeons Lucas
Krauel and José Antonio
González after CEB-01 first
implantation in human,
August 2020
1. Product. Medical need – Cebiotex solution: CEB-01
When the Oncological Surgeon removes a cancerous tumor,
there is a MEDICAL NEED to ensure that the surgical site is
free of cancer cells.
CEB-01 aims to SOLVE this medical need, with local control
after oncological surgery, avoiding the viability of possible
cancer cells that may have remained after the surgical
intervention. This is implanted in the surgical act in just 4
minutes, and makes a therapeutic "RELEASE" WITHOUT
TOXICITY, from minute 0 to 4-5 weeks, which are those in
which there is no type of treatment at present.
CEB-01 (categorised as a medicinal product) is formed by a
3D structure of nano-fibers of biocompatible and
biodegradable material (PLGA), loaded with the cytostatic
SN-38. The membrane, after releasing the cytostatic locally,
biodegrades and disappears.
SN-38 is extremely effective in 30 different types of cancer,
including Sarcomas, Neuroblastoma, Ewing sarcoma,
Glioblastoma, pancreas, ovary, breast, kidney, liver among
other.
January 2021, 4th financing round, Cebiotex summary
Product. CEB-01, extremely promising efficacy
• The results obtained in the in-vivo tests,
efficacy animal models, confirm the antitumor
therapeutic effect of SN-38 loaded in the CEB-
01 membrane and released locally, in tumor
lines of the Pancreas, soft tissue sarcomas
Invivo efificacy Pancreas +
and Ewing Sarcoma.
chemotherapy
• The data obtained at the beginning of
Clinical Phase I in humans, so far,
corroborates the release of SN-38 observed in
animal models.
• Observing a release, in humans, slightly
more sustained over time, with respect to
Invivo efficacy STS +
animal models. Being able to arrive 4 - 5
chemotherapy
weeks of therapeutic release .
Invivo efficacy Ewing Sarcoma
January 2021, 4th financing round, Cebiotex summary
Product. CEB-01
neither toxicity, nor
side effects
In GLP regulatory toxicity studies in
animals, it was observed that:
a) The histological findings are the
typical changes described in the
literature associated with the
“bioresorption” of PLGA and are
observed very frequently in
operated patients in whom this
material is used.
b) No differences have been
evidenced between membranes The Regulatory Toxicology Tests, developed at MPI
loaded with drug and those Research (USA), have confirmed the results of non-systemic
without drug, so it can be toxicity and foreign body reaction in local toxicology, which
assumed that in the organs allowed us to initiate the Clinical Phases.
studied, without underlying ✓ In the Clinical Phases in humans, started in august, 2020,
pathology, SN-38 does not so far, no toxicity or side effect has been observed,
produce discernible histological confirming the results obtained in animals.
effects with optical microscopy
study.
January 2021, 4th financing round, Cebiotex summary
Product,
Regulatory CEB-01:
• CTA approved by the AEMPS;
• Started the Clinical Study in STS indication
✓CTA approved by the AEMPS (Spanish agency of medicinal
and health products).
✓ Obtained the Orphan Drug certification for CEB-01 "Orphan
Designation or ODD", by the EMA / EC.
✓ The Phase I Clinical Study, safety, started with 9 patients at
the Sant Pau Hospital in Barcelona.
✓ Incorporated into SAB Cebiotex the main world medical and
surgical key opinion leaders in STS.
The objectives of the current funding round (October 2020) are:
o Complete Clinical Phase 2a, activity, in Sarcomas (STS),
total: 21 adult patients.
o Initiate the Clinical Phase in Childhood cancer, hand in
hand with SJD Pediatric Cancer Center Barcelona with the
approval of the PIP.
o FDA: ODD (Orphan Drug Designation) – preIND meeting.
January 2021, 4th financing round, Cebiotex summary
Product. Technology and manufacturing
process: GMP granted
CEBIOTEX has developed and manufactured its own production
technology, with the collaboration of UPC.
The manufacturing technology, property of Cebiotex are installed in the
facilities of the pharmaceutical company PrasFarma, for the production
of the Pharmaceutical Batches, which are delivered to the Sant Pau
Hospital for their implantation in the patients of the Clinical Study.
CEB-01 production process have been granted with the GMP
Certificate from the AEMPS, mandatory requirement to start clinical
trials.
The CEBIOTEX® Technology Platform, GMP, is property of Cebiotex.
Forming part of its industrial property, being the only one of its kind in
the market.
The objectives for the present funding round are:
1. Production of the required CEB-01 batches to complete the
clinical objectives
2. Develop the industrial scalability of production equipment to
adapt them to the production needs of clinical batches in phase
IIb and the subsequent production required once CEB-01 is
marketed.
January 2021, 4th financing round, Cebiotex summary
2. Modelo de Negocio
DRUG
IN-VIVO PRE-CLINICAL PHASE I PHASE II PHASE III
DISCOVERY
DEAL
CEBIOTEX's Business Model is based on developing its products until reaching a sub-license agreement (DEAL), or a
sale with a Company interested in them. In the pharmaceutical sector, it is currently common to reach the DEAL once
the products have reached Phases I / II of clinical development, that is, they have been tested in humans, with
licensed or purchasing Pharmaceutical Companies developing the product up to Phase III , register and launch it on
the market.
a) LICENSE either:
1. First candidate CEB-01
2. CEBIOTEX® platform, applied to oncology
3. CEBIOTEX® platform, oriented to other medical applications (Antibiotics, Cell Therapy)
b) M&A, totally or partially the Company.
January 2021, 4th financing round, Cebiotex summary
Product portfolio (current and forecast)
Cebiotex, due to its birth motivation, has the intention to support that the products that it
develops for adults arrive to pediatric application
DRUG
IN-VIVO PRE-CLINICAL PHASE I PHASE II PHASE III
DISCOVERY
Adult Pediatric
SOFT TISSUE NEUROBLASTOMA
CEB-01 SARCOMA EWING SARCOMA
GLIOBLASTOMA
CEB-01 GLIOBLASTOMA
MULTIFORME
Other cancer
DRUG indications
DISCOVERY CEB-03
Infections, advanced
therapies
January 2021, 4th financing round, Cebiotex summaryCEB-01 market
Our TAM (Total Available Market) considers global
patients for potential first-line indications for CEB-01:
STS, glioblastoma, lung, breast, colorectal,
pancreas, and ovarian cancer worldwide. There are
about 7,333,426 patients.
Our SAM (Serviceable Available Market) includes all
STS patients in the US and EU5. The main
developed markets considered the US and EU5
(France, Germany, Italy, Spain, UK) account for 74%
of spending on cancer drugs. These will also be our
initial target markets (which will later expand to the
rest of Europe, LATAM and Asia Pacific).
Our SOM (Serviceable Obtainable Market) considers
that based on our own “Patient Model” we can reach Cancer type New cases Deaths 5 years survival
in 2028 (1st year of commercialization) an
rates
obtainable market of 1,525 patients in the EU5 and
the USA, considering a patient participation of 2.5% STS 250.000 97.500 < 50%
in new patients and 0.8% in patients previously
Glioblastoma 296.851 241.037 20%
diagnosed with STS. This proportion of patients will
grow exponentially during the following Small cell lung 6%
commercialization years with 2032 as the peak year 2.093.876 1.761.007
cancer
(10% 2028, 20% 2039, 40% 2030 and 60% 2031 in
new STS patients and 3% 2028, 7% 2029, 13% 2030 Breast 2.088.849 626.679 90%
and 20% 2031 in patients previously diagnosed with
Colorectal 1.849.518 880.792 63%
STS).
Pancreas 458.918 432.242 9%
Ovarian 295.414 184.799 47%
Total 7.333.426 4.224.056
January 2021, 4th financing round, Cebiotex summary4. CEB-01 Competitors. Products already in the market
Gliadel wafer: Indicated for the local control of the surgical
bed after cranial surgery of glioma multiforme (does not
apply to any other indication). PV $ 31,000 in US and €
10,000 EU.
The Medicine Agencies authorize its use because it gives an
additional life expectancy of 2 months to treated patients.
Side effects and toxicity are very important, which
implies that it is in clear decline in the market.
Radiotherapy and Local Radiotherapy
Manufacturers are investing in the development of new equipment that is
more effective in radiating the areas to be treated in a more controlled
and precise way. Faced with this type of therapy, it is worth noting the
"terrible" side effects of radiation therapy. By all known. Likewise, the
cost of acquisition (approx. € 20M depending on models) and
maintenance of the equipment are very high. Very few hospitals can
purchase equipment and prepare operating rooms to administer Local
Radiotherapy.
NBTX-TOPO: nano-particles formulated as a
gel, which are previously introduced into the
area to be treated by radiotherapy. Giving
greater efficiency and reducing its toxicity.
January 2021, 4th financing round, Cebiotex summaryCEB-01 competitors in early development
Teams of researchers, worldwide, are working on the development of new products based on nano-technology, in
order to deliver anti-cancer molecules directly to tumor cells. Examples:
Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue
SN38. (Ian Wark Research Institute, University of South Australia, Mawson Lakes, SA,
Australia; Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical
Sciences, Monash University (Parkville Campus), Australia).
Nanoparticle delivery of an SN38. (The Children's Hospital of Philadelphia)
3D Superhydrophobic Electrospun Meshes as Reinforcement Materials for Sustained
Local Drug Delivery Against Colorectal Cancer Cells. (Departments of Biomedical
Engineering and Chemistry, Boston University, Boston).
January 2021, 4th financing round, Cebiotex summaryMain drawbacks of the competitors already in the market:
Current adjuvant treatments Main drawbacks
§ Toxicities to healthy tissues/organs.
Systemic chemotherapy.
§ Low achievable drug concentrations at tumour sites.
Drugs given 4 weeks after surgery.
§ Generate drug resistant mechanisms.
External beam radiotherapy. § Destroys healthy cells, many very serious side-effects.
Radiation given 2-3 weeks after surgery § Very costly: ~15.000€.
Brachytherapy § Cumbersome administration, nearby tissue effects.
Radioactive seeds or wires are placed in § Problems with radiation handling and toxicity, limited availability
surgery site after resection § Very costly: 7.500€-19.000€ plus costs of the associated surgery.
§ Requires complex shielding to internal organs and surgical team.
§ Needs substantial training.
Intraoperative radiotherapy
§ Damages to surrounding healthy cells/tissues.
Radiation applied during surgery
§ Very costly (~15.000e).
§ Not common at hospitals (e.g. only 2 units in Spain).
§ Has begun to be studied for STS therapy but is not yet approved.
Proton Therapy
§ Damages surrounding healthy cells/tissues.
Radiotherapy that uses energy from
§ Very costly (30.000€-120.000€).
positively charged particles (protons)
§ Considered one of the single most expensive medical devices.
January 2021, 4th financing round, Cebiotex summaryMain drawbacks of the competitors currently in development phase
Emerging treatments under Main drawbacks
development
§ Their manufacturing process should generate serious issues
in terms of polymer/solvent/active-substance interaction
Wafers, hydrophobic meshes, hydrogels
§ The drug delivery rate is restricted by the polymer
and nanofibers/ microcapsules
degradation rate.
Local delivery systems in early phase of
§ They usually lack a controlled release or mechanical stability.
development
§ Very difficult to enter in medical practice in the next several
years.
§ Very costly and require a technically difficult process.
Cell immunotherapy § Its effects only observed in a limited number of patients.
§ No significant clinical benefit described in patients with STS.
January 2021, 4th financing round, Cebiotex summaryCEB-01 competitive advantages
CEB-01 is the first local control system for STS whose safety,
tolerability and efficacy have been demonstrated and validated
in preclinical regulatory studies. Furthermore, the first results from
phase I of the First in Man clinical trial indicate that the patients
did not have toxicity or postsurgical complications associated
with CEB-01. Finally, we have our own GMP qualified machine for
production, and the production process and final product are
GMP certified. There is no other product like this on the market.
CEB-01 exhibits the following best results compared to the
existing state of the art:
1) Reduction of tissue margins to be removed from the tumor
site.
2) Prevent mutilation surgeries that can drastically affect the
functionality of a limb (for example, mobility in STS located
within a muscle bundle).
3) Reducing the risk or even avoiding the recurrence of STS.
4) Decrease in the use of adjuvant radiotherapy and reduction
of postoperative chemotherapy.
5) Reduction of general treatment costs.
6) Increase the life expectancy of patients and the quality of life
by extending the time they are free of disease.5. Intelectual Property Rights
Protecting the product and local drug delivery system:
Nonwoven membrane as a drug delivery Granted
EP2644191B1 Applic. # EP12162338 Europe
system; priority March 30, 2012 (08/2016)
Nonwoven membrane as a drug delivery Granted
US 9,561,190 B2 Applic. # 14/389,330 USA
system (07/2017)
Nonwoven membrane as a drug delivery Granted
EP3108881B1 Applic. # EP16178875.5 Europe
system (07/2017)
Applic. # Nonwoven membrane as a drug delivery Granted
CN104321051B China
CN201380027164.7A system (09/2018)
Nonwoven membrane as a drug delivery Granted
CN108992432A Applic. # EP12162338.3A China
system; divisional patent (12/2018)
Beaded non-woven membrane as a
PCT Inter-
TBD Applic. # EP18382589 drug delivery system; priority Aug. 30,
(08/2019) national
2018
Protecting the production system and method:
Sistema y método para producir fibras Granted
ES2534491B1 Applic. # P201300654 Spain
por electro-hilado (03/2016)
January 2021, 4th financing round, Cebiotex summary6. Main milestones achieved by Cebiotex:
ü CEBIOTEX® technology platform, patented in the EU,
USA and China.
ü Last PCT patent, granted in 2019, national phases:
February 2021.
ü ODD granted by EC / EMA in STS indication for CEB-
01. Renovated in August 2020
ü GMP certification granted to produce Matrix Implants,
CEB-01. The technology and production processes are
the property of Cebiotex, an industrial secret.
ü CTA - Authorization to start Clinical Trials of CEB-01 in
STS indication, Phase I (safety-dose), 9 patients, plus
extension of 12 patients, Phase 2a (activity).
ü Clinical trials started in August, 2020, at the Sant Pau
Hospital in Barcelona, with extremely promising results.
ü Cebiotex has raised € 4.3M since the start of activity in
2015, with 3 financing rounds.
January 2021, 4th financing round, Cebiotex summary7. Team
Joan Bertran, MBA (CEO, Co-founder). Textile Industrial Engineer with more than 20 years of experience in
the textile sector, mainly as Manager of Operations, but also in R&D and Product Development. Joan holds
a master’s in Operations Management from EADA and an MBA from the Catalan Institute of Technology.
José Antonio Tornero, PhD (CTO, Co-founder). PhD in engineering, mechatronics Engineer. Expert in electro
spinning nanofiber production. Director of the Systems and Process Laboratory at the Institute for Textile
Research (INTEXTER) at the Polytechnic University of Catalonia (UPC).
Lucas Krauel, MD, PhD (CMO, Co-founder). A paediatric surgeon for over ten years, he studied medicine at
the University of Barcelona and now leads the paediatric oncology surgery program at Sant Joan de Déu
Hospital. He was a Fellow in Paediatric Surgical Oncology at Memorial Sloan Kettering Cancer Center.
Jaume Mora MD PhD. Medical doctor, co-founder and Chairman in the Scientific Advisory Committee.
Scientific director in the area of Onco-Hematologi of the Hospital Sant Joan de Déu de Barcelona.
Alumni Pediatric Hematology and Oncology; Molecular Pathology. Memorial Sloan Kettering Cancer Center,
New York.
January 2021, 4th financing round, Cebiotex summaryLuc Marti, PhD, MBM (COO, shareholder). Holds a PhD in Pharmacology and a Master’s in Biotech
Management. Was VP, R&D Operations at Artax Biopharma (USA) where he developed a therapy for
autoimmune up to phase Ib. He cofounded Genmedica Therapeutics which developed an antidiabetic up to
phase IIa. Over 25 years’ experience in pharmacology, of which 15 in drug development. Obtained 7
clinical trial authorisations.
Imma Barber (CBO). Biologist, MBA, Postgraduate in Marketing Management and Specialized in
Entrepreneurship and Innovation. Pharmaceutical executive with more than 20 years of experience in
national and international senior positions on several therapeutic diseases – Oncology, Central Nervous
System, etc – mainly in big pharma. Expert in Alliance Management had been involved in a list of product
evaluations, due diligences, acquisitions, and co-promotions.
Júlia Dotras (Communication Manager). Master’s degree in Media Practice for Development and Social
Change at the University of Sussex. Work experience in digital health communications, creating and
developing written and visual content, supporting a range of projects as well as digital and social media
campaigns.
Javier Merino PhD. (Legal Advisor), Secretario del Consejo Administración de Cebiotex y Cebfunding. Institut
Superieur de Gestion, Paris.
Dedicación parcial. Fundador y Managing Partner de Innovatech Law Firm. Anteriormente,
Baker&McKenzie; Clifford Cance LLP; Osborne Clarke. Ha ejercido como docente en temas relacionados
con la Protection of Industrial and Intellectual Property, Technology transfer and Licensing, Personal Data.
January 2021, 4th financing round, Cebiotex summaryAdvisors
Xavier Luria MD. Cebiotex Drug Development Regulatory Affers Advisor.
Senior consultant DDR Barcelona-London. He has been exposed to this area from a triangle perspective: as
a hospital’s medical doctor with postgraduate training in internal medicine, as clinical researcher and
management and leadership positions in pharma industry and, finally, as relevant European Medicines
Agency (EMA) manager.
Jordi Petit Salamó. Licenciado ADE y MBA, Esade (Barcelona). CEMS master, HEC (París).
Cebiotex Financial Advisor.
Twenty-five years of corporate finance experience, with a focus on investment and strategy, particularly for
SMEs in development and expansion. Served as partner at Vantum Corporate, with past positions at KPMG,
Akzo Nobel, Caixa Capital Risc and Oryzon Genomics.
Antonio Perez, MD, PhD.
Director of Development, Medical Director and/or Coordinator of the Scientific Committee in several
pharmaceutical companies and/or biotechs, in oncology, infectious diseases, digestive, nervous system,
orphan indications, among other areas, including international clinical developments, from phase 1 to 4 ,
registered and/or sold in the most important markets (Europe, USA, Asia, Africa).
January 2021, 4th financing round, Cebiotex summaryScientific Advisory Board
Dr. Antonio López Pousa MD PhD
Clinical Head & Senior Consultant Medical Oncology Dept. Hospital de la Santa Creu i Sant Pau de
Barcelona.
Dr. José Antonio González MD PhD
Jefe Cirugía Servicio de Oncología Médica. Hospital de la Santa Creu i Sant Pau de Barcelona..
Dra. Ana Sebio MD, PhD
Oncología Médica en Sarcomas. Hospital de la Santa Creu i Sant Pau de Barcelona.
Dra. Silvia Stacchiotti MD PhD
Works in Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale Tumori. She is the Principal
Investigator and Coinvestigator of several trials on Sarcoma and GIST. She is a member of Soft Tissue &
Bone Sarcoma Group, ESMO, CTOS and of ASCO. She has authored more than 100 scientific publications
on sarcoma.
Dr. Alessandro Gronchi, MD PhD
Fondazione IRCCS Istituto Nazionale dei Tumori Milan. Memorial Sloan Kettering Cancer Center NY in 2002.
He has been chair of the Sarcoma Service at the National Cancer Institute He serves as chair of the STS
committee of the ISG, … ; he is a member of ESSO, ASCO, … He is one of the initiators of Trans-Atlantic
RetroPeritoneal Sarcoma Working Group. He has authored more than 280 scientific publications.
Dr. Robert Maki MD PhD FACP
Sarcoma Program Lead; Director, Center for New Cancer Therapies; Monter Cancer Center, Northwell
Health and Cold Spring Harbor Laboratory; Cornell University Medical College; Nueva York.
January 2021, 4th financing round, Cebiotex summary8. Shareholders
The Cebfunding S.L. groups together the minority partners of Cebiotex. It is made up of 292 partners, focusing its
activity solely on investing and collecting benefits from CEBIOTEX S.L. Joan Bertran is its Sole Administrator.
The Institutions, the Sant Joan de Déu Foundation of Barcelona and the Polytechnic University of Catalonia, are
part of the company CEBIOTEX S.L.
The Ship2B Foundation, VC and 2 Family Offices are also part of Cebiotex.
January 2021, 4th financing round, Cebiotex summary9. 4th Financing round, funding needs:
DRUG
IN-VIVO PRE-CLINICAL PHASE I PHASE II PHASE III
DISCOVERY
January 2021, 4th financing round, Cebiotex summary4th Financing round, conditions:
DRUG
IN-VIVO PRE-CLINICAL PHASE I PHASE II PHASE III
DISCOVERY
Value of the financing round:1,60M€.
✓ Closed with over financing of € 2.22 million, (December 2020)
Once the investment round is closed with € 2.22 million of capital, the objective is to
achieve a public financial leverage of at least 50%.
a) Scientific Objective: Clinical Phase 2 (activity) in Sarcomas (STS), adults. (Hospital Sant Pau in
Barcelona - Dr. Antonio López Pousa MD PhD).
b) Business Objective: 1st window of opportunity for EXIT in 2023. Licensing, or, M&A.
c) Strategic Objective: Initiate Clinical Phases in Childhood cancer, hand in hand with SJD
Paediatric Cancer Centre Barcelona; ODD and preIND meeting in FDA.
January 2021, 4th financing round, Cebiotex summary10. Estrategia de Salida, EXIT
Comparable License agreements that have been closed with
pharmaceutical companies in recent years include:
The exit strategy for investors, as mentioned Development
in point 2. Business Model, is as follows: Year Company Buyer/license Deal Terms
Stage
a) LICENSE either: 2010 Biocompatibles BTG Market M&A. $ 283 M
1. First candidate CEB-01 2014 Nordion BTG Market Asset transaction. $ 200M.
2. CEBIOTEX® platform, applied to
$2M in shares + $2M trade-payables
oncology Azaya
2016 Citori Phase I/II + $ 100M cap +5year lease
3. CEBIOTEX® platform, oriented to Therapeutics
manufacturing & dev. facility
other medical applications
(Antibiotics, Cell Therapy)
$13M investment + $343 regulatory &
2017 CytRx Nantcell Phase III
commercial milestones + royalties (
b) M&A, totally or partially the Company.
Phase III
In this 4th Funding Round, there is a 1st exit Karyopham
Antengene Corp. Targeted
$12M + $150M in milestones +
2018
opportunity estimated for 2023-24. Therapeutics royalties)
therapy
A set of Licenses is contemplated for CEB-
2018 Sirtex Varian Medical Market M&A. $1.3 bn.
01, or an M&A, estimating an approximate
total value of about 60MM EUR and a return $20M (for minority stake) + up to
Taiwan LiposomeJixi Agrosino
for investors x10. 2018 Phase II $50M before drug approval + $60M
Company (TLC) Biotech
milestones
Taiwan Liposome
2019 3SBio R&D - Phase I $25M/product+ milestones+ royalties.
Company (TLC)
January 2021, 4th financing round, Cebiotex summaryContacto:
CEBIOTEX S.L.
Joan Bertran Llavina (CEO)
Pier01, Barcelona Tech City
Email: jbertran@cebiotex.com
Plaça de Pau Vila, 1
Email: info@cebiotex.com
08039 BarcelonaYou can also read
